ArticleBrain and behavior2025
Acute Anxiolytic Effects of Salvia Heldreichiana Essential Oil in Rats: Reduction in Serum Cortisol.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Integrated Metabolomics and Bioactivity Approach to Characterize Salvia heldreichiana and Salvia tomentosa Extracts.ChemistryOpen · 2026Article
- Article
- Acute Anxiolytic Effects of Salvia Heldreichiana Essential Oil in Rats: Reduction in Serum Cortisol.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe rapid onset of anxiolytic drugs without cognitive or motor impairments remains an unmet need. This study evaluated the acute anxiolytic effects of Salvia heldreichiana essential oil in rats, measuring anxiety-related behaviors, hippocampal levels of serotonin, noradrenaline, gamma-aminobutyric acid GABA, and serum cortisol.
methodForty-eight male Wistar albino rats were divided into two experiments. Experiment 1 (n = 24) tested a single dose (200 mg/kg, oral gavage) of Salvia heldreichiana essential oil, while Experiment 2 (n = 24) evaluated repeated doses (200 mg/kg/day for five days, oral gavage). Anxiety-like behavior was assessed using the open field and elevated plus maze (EPM) tests. Sedation and motor coordination were measured via the rotarod test. Neurochemical analysis included hippocampal noradrenaline, serotonin, GABA levels, and serum cortisol. Potential toxicity was monitored through ALT, AST, creatinine, and BUN levels.
findingsSalvia heldreichiana essential oil significantly reduced serum cortisol levels (p < 0.05) and showed a trend toward increased hippocampal serotonin levels, similar to diazepam. No sedative or motor impairing effects were observed, and no hepatotoxic or nephrotoxic effects were observed at the administered dose.
conclusionSalvia heldreichiana essential oil showed promise as a rapid-onset anxiolytic, as it reduced cortisol levels and may increase serotonin, all without causing motor impairments. Further studies with conditioned anxiety models are required to confirm these effects and elucidate underlying mechanisms. SIGNIFICANCE STATEMENT: This study highlighted the potential of Salvia heldreichiana essential oil as a rapid-onset anxiolytic with minimal side effects. The oil significantly reduced serum cortisol levels, a key biomarker of stress, and showed a trend toward increased serotonin levels in the hippocampus, contributing to its anxiolytic effects, paralleling mechanisms observed in conventional anxiolytic medications. Unlike many existing treatments, Salvia heldreichiana did not induce sedation or impair motor coordination, highlighting its promise as a safer alternative for anxiety management. These findings suggested the essential oil could address the unmet need for fast-acting anxiety treatments without cognitive or physical drawbacks, making it relevant for both clinical and general use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.